| 000 | 01783 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250515004602.0 | ||
| 264 | 0 | _c20060209 | |
| 008 | 200602s 0 0 eng d | ||
| 022 | _a0300-0664 | ||
| 024 | 7 |
_a10.1111/j.1365-2265.2005.02372.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBronstein, M | |
| 245 | 0 | 0 |
_aPharmacokinetic profile of lanreotide Autogel in patients with acromegaly after four deep subcutaneous injections of 60, 90 or 120 mg every 28 days. _h[electronic resource] |
| 260 |
_bClinical endocrinology _cNov 2005 |
||
| 300 |
_a514-9 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAcromegaly _xdrug therapy |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAnalysis of Variance |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xpharmacokinetics |
| 650 | 0 | 4 | _aDelayed-Action Preparations |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aGels |
| 650 | 0 | 4 |
_aGrowth Hormone _xblood |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInjections, Subcutaneous |
| 650 | 0 | 4 |
_aInsulin-Like Growth Factor I _xanalysis |
| 650 | 0 | 4 | _aLinear Models |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPeptides, Cyclic _xpharmacokinetics |
| 650 | 0 | 4 |
_aSomatostatin _xanalogs & derivatives |
| 700 | 1 | _aMusolino, N | |
| 700 | 1 | _aJallad, R | |
| 700 | 1 | _aCendros, J M | |
| 700 | 1 | _aRamis, J | |
| 700 | 1 | _aObach, R | |
| 700 | 1 | _aLeselbaum, A | |
| 700 | 1 | _aCatus, F | |
| 773 | 0 |
_tClinical endocrinology _gvol. 63 _gno. 5 _gp. 514-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/j.1365-2265.2005.02372.x _zAvailable from publisher's website |
| 999 |
_c15894222 _d15894222 |
||